Ricerca Announces ISO 9001 Certification

CONCORD, Ohio--(BUSINESS WIRE)-- Ricerca Biosciences, a uniquely integrated preclinical contract research drug development company providing services to the pharmaceutical industry, is pleased to announce that its Ricerca France, Lyon facility, has recently obtained the ISO 9001:2008 certification for all activities performed at the site.

In addition, Ricerca Taiwan, Taipei facility, also successfully passed the ISO 9001:2008 certification in October 2009.

International Organization for Standardization (ISO) is the world’s largest developer and publisher of international standards. It is a non-governmental organization that forms a bridge between public and private sectors, enabling a consensus to be reached on solutions that meet both the requirements of business and the broader needs of society.

The ISO 9000 family, including the ISO 9001, addresses the requirements for implementing an efficient quality management system. This standard ensures that the organization fulfills and achieves continual improvement of its performance in pursuit of the customer’s requirements, applicable regulatory requirements and enhancement of customer satisfaction.

“As a recipient of this certification, our concern and thorough attention to our client needs are evident. Ensuring our discovery and development services meet the standards required of us and those we guarantee to our clients enables Ricerca to continue to be the trusted CRO in this industry,” stated Chairman and CEO of Ricerca, Ian Lennox.

Ricerca offers a unique spectrum of services for the areas of agrochemical registration, environmental analysis and pre-investigational new drug (IND) biopharmaceutical registration.

About Ricerca Biosciences

Ricerca Biosciences offers a comprehensive suite of discovery and preclinical services to support drug candidates from discovery through IND on a global scale, including capabilities in discovery and medicinal chemistry, API process chemistry, cGMP manufacturing and scale-up, IND-enabling toxicology, molecular profiling, pharmacology/DMPK and drug safety assessment services. With facilities in Concord, Ohio; Bothell, Washington; Taipei, Taiwan; and Lyon, France, Ricerca offers scientific excellence through reliable, cost-effective strategies to accelerate your drug discovery programs.



CONTACT:

Kelly Sladek
SCORR Marketing
308.237.5567
[email protected]

KEYWORDS:   United States  Europe  North America  France  Ohio

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical  Research  Science

MEDIA:

Logo
 Logo

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.